

ISOLATION AND STRUCTURE OF DOLASTATIN 17^{1a,b}George R. Pettit,^{*} Jun-Ping Xu, Fiona Hogan, and Ronald L. Cerny*Cancer Research Institute and Department of Chemistry, Arizona State University, Tempe, Arizona 85287-1604, USA*

Abstract - The unusual cyclodepsipeptide dolastatin 17 (1) was isolated from the Papua New Guinea sea hare *Dolabella auricularia* and found to contain a new acetylenic β -amino acid designated dolayne (Doy). Dolastatin 17 exhibited significant human cancer cell growth inhibitory activity (GI_{50} 0.45-0.74 μ g/mL range).

Marine invertebrates, especially sea hares,^{2,3} sponges^{4,5} and tunicates,⁶ continue to offer a most promising⁷ array of potentially useful antineoplastic agents such as the dolastatins,^{1,3} criamides,⁴ hemiasterlins,⁴ arenastatin A⁵ (a cryptophycin⁸), and patellamides.⁶ Herein we report that an extensive investigation of the shell-less mollusk *Dolabella auricularia* (Aplysiidae) collected (1983) in the Bismarck archipelago of Papua New Guinea has led to isolation of the novel cyclodepsipeptide, dolastatin 17 (1), bearing a new acetylenic β -amino acid designated dolayne (Doy).





Figure 1: Dolastatin 17 (1) key HMBC (↔) and NOE (↷) correlations.

A murine P388 lymphocytic leukemia cell-line-active fraction prepared from 1000 kg. (wet. wt.) of *D. auricularia* was separated as briefly described for the isolation of

dolastatin 16.¹ Final purification and isolation of dolastatin 17 (1, 2.3 mg., 2.3 x 10⁻⁷% yield) was realized by employment of reversed-phase (C8) HPLC to afford cyclodepsipeptide (1) as a colorless amorphous powder: $[\alpha]_D -145^\circ$ ($c = 0.14$, CH₃OH) and FTIR ν (NaCl): 3350, 2900, 2116, 1740, 1643, and 1520 cm⁻¹. The IR spectral data (ν 2116 cm⁻¹) suggested that dolastatin 17 contained an alkyne group. The HRFAB mass spectrum afforded a quasi-molecular ion at m/z 774.500914 $[M+H]^+$ which corresponded to the molecular formula C₄₁H₆₇N₅O₉. All 1D- and 2D-NMR spectra of 1 were measured in two solvents (CDCl₃ and DMSO-*d*₆). Analysis of the two series of ¹H-NMR, APT H COSY, TOCSY and HMQC (500 MHz) spectra combined with the HMBC, NOESY and ROESY NMR spectral results established the presence of seven independent spin systems: one Pro, one Leu, two MeVal, two 2-hydroxyisovaleric acid (Hiv) units and a new β -amino acid (Doy) unit with a terminal alkyne group. The partial molecular formula of the new Doy unit was found to be C₈H₁₁NO by HRFAB mass spectral analysis. Interpretation of cross peaks (Figure 1) observed in the 2D-NMR spectra led to the assignment of 3-amino-7-octynoic acid (Doy) for the new and unique β -amino acid unit. Such a β -amino acid having an alkyne group is rarely encountered in marine invertebrates. Interestingly, the mollusk *Onchidium* sp. collected off New Caledonia has been found to contain the dimeric cyclic depsipeptide onchidin (2) that contains a methyl side



Onchidin (2)

chain derivative of Doy.⁹ The key HMBC correlations: CH₃N[MeVal²]/CO[Pro¹], α H[Hiv³]/CO[MeVal²], CH₃N[MeVal⁴]/CO[Hiv³], NH[Leu⁵]/CO[MeVal⁴], α H[Leu⁵]/CO[MeVal⁴],

Table 1: The ^1H - and ^{13}C -NMR Spectral Data Assignments of Dolastatin 17 (in CDCl_3)

No.	^{13}C ppm	^1H ppm	J Hz	HMBC (^1H to ^{13}C)	No.	^{13}C ppm	^1H ppm	J Hz	HMBC (^1H to ^{13}C)
<i>Pro</i> ¹ CO	171.81 s				γ ¹	19.83 q	0.95 d (7.0)		α, β, γ
α	57.27 d	5.12 dd (9.0, 5.0)		CO, β, γ	CH_3N	29.81 q	2.92 s		Hiv ³ CO, CO
β	29.68 t	1.80 m		CO	<i>Leu</i> ⁵ CO	172.08 s			
		2.38 m		CO	α	51.64 d	4.60 m		MeVal ⁴ CO, CO, β, γ
γ	24.81 t	2.00 m		α, β, δ	β	38.39 t	1.68 m		γ, δ, δ'
δ	47.06 t	3.55 dd (9.0, 7.5)		α, β	γ	24.65 d	1.61 m		β, δ, δ'
		3.69 m		α, β	δ	23.59 q	0.86 q (7.0)		β, γ, δ'
<i>MeVal</i> ²					δ'	20.87 q	0.84 q (7.5)		β, γ, δ
CO	171.27 s				NH		7.25 d (7.8)		MeVal ⁴ CO, α
α	64.51 d	4.23 d (8.5)		Pro ¹ CO, CO, β	<i>Doy</i> ⁶ CO	170.17 s			
				$\gamma, \gamma', \text{CH}_3\text{N}$	α	39.51 t	2.27 m		CO, β, γ
β	29.47 d	2.35 m		α, γ, γ'			2.79 dd (16, 6)		CO, β, γ
γ	20.43 q	1.20 d (6.5)		α, β, γ'	β	45.32 d	4.32 m		
γ'	21.40 q	1.07 d (7.0)		α, β, γ	γ	33.99 t	1.52 m		α, β, ϵ
CH_3N	30.49 q	2.92 s		Pro ¹ CO, CO, α			1.64 m		α, β, ϵ
<i>Hiv</i> ³ CO	169.54 s				δ	24.48 t	1.52 m		
α	76.60 d	5.21 d (3.0)		MeVal ² CO, CO	ϵ	18.18 t	2.16 m		γ, ζ
				β, γ, γ'	ζ	68.43 s			
β	28.92 d	2.14 m		γ, γ'	ξ	84.20 d	1.91 s		ϵ
γ	20.07 q	1.10 d (7.0)		α, β, γ'	NH		6.10 d (7.8)		Leu ⁵ CO, α, β
γ'	16.31 q	0.99 d (7.0)		α, β, γ	<i>Hiv</i> ⁷ CO	167.20 s			
<i>MeVal</i> ⁴					α	76.17 d	5.03 d (3.0)		Doy ⁶ CO, CO, β, γ, γ'
CO	168.98 s				β	29.47 d	2.35 m		γ, γ'
α	62.15 d	4.68 d (10)		Hiv ³ CO, CO, β, γ, γ'	γ	16.21 q	0.98 d (7.0)		α, β, γ'
β	25.58 d	2.30 m		α, γ, γ'	γ'	20.02 q	1.02 d (7.0)		α, β, γ
γ	17.91 q	0.78 d (6.5)		α, β, γ'					

NH[Doy⁶]/CO[Leu⁵] and $\alpha\text{H}[\text{Hiv}^7]/\text{CO}[\text{Doy}^6]$ led to the dolastatin 17 (1) structural assignment: Pro¹-MeVal²-O-Hiv³-MeVal⁴-Leu⁵-Doy⁶-O-Hiv⁷. The sequence of peptide bonds identified by the HMBC correlations was further confirmed by NOESY and ROESY experiments. An nOe relationship from δ 3.69 ($\delta\text{H}_1\text{-Pro}^1$) and δ 3.55 ($\delta\text{H}_2\text{-Pro}^1$) to δ 5.03 ($\alpha\text{H-Hiv}^7$) revealed that the carbonyl carbon of Hiv⁷ was linked through the nitrogen of Pro¹. That established dolastatin 17 (1) as a cyclic depsipeptide.

Evidence supporting a cyclic depsipeptide structure was also obtained by consideration of the molecular formula unsaturation numbers.

An hydrolysis procedure (6N HCl) and chiral analyses (CHIREX phase 3126) established the Leu, Pro, MeVal and Hiv amino acid and hydroxy acid units as all L(S).^{10,11} The difference in chemical shifts of the β - and γ -carbons of Pro¹ ($\Delta\delta_{\beta\gamma}$ = 4.87 ppm) pointed to the presence of a *trans*-Hiv⁷-Pro¹ configuration.¹²

Dolastatin 17 (1) was found to display significant human cancer cell growth inhibitory activity against ovary OVCAR-3 (GI₅₀ 0.67 μ g/mL), brain SF-295 (GI₅₀ 0.55 μ g/mL), lung HCl-H460 (GI₅₀ 0.74 μ g/mL) and melanoma KM20L2 (GI₅₀ 0.45 μ g/mL). Eventual total synthesis of dolastatin 17 (1) will allow further biological studies and assignment of the Doy (presumably *S* configuration as in dolastatin 15)² absolute configurations.

ACKNOWLEDGMENTS

With appreciation we record the following very necessary financial support provided by Outstanding Investigator Grant CA44344-01-09 awarded by the Division of Cancer Treatment Diagnosis and Treatment Centers, NCI, DHHS, the Arizona Disease Control Research Commission, the Fannie E. Rippel Foundation, Virginia Piper, the Robert B. Dalton Endowment Fund, Eleanor W. Libby, Gary L. Tooker, Diane M. Cummings, John and Edith Reyno, Lottie Flugel, Polly Trautman, the Fraternal Order of Eagles Art Ehrmann Cancer Fund and the Ladies Auxiliary to the Veterans of Foreign Wars. For other very useful assistance we are pleased to thank the Government of Papua New Guinea (Andrew Richards and Navu Kwapena), Drs. Charles Chapuis, Cherry L. Herald, and Ron Nieman, Mr. Larry Tackett, Mrs. Denise Nielsen-Tackett, Mrs. Kim M. Weiss, and Mr. Lee Williams, the U.S. National Science Foundation (Grants BBS 88-04992, CHE-8409644), and the NSF Regional Instrumentation Facility in Nebraska (Grant CHE-8620177)

REFERENCES

1. a) Antineoplastic Agents AA369. For part 368 refer to: G. R. Pettit, J.-P. Xu, F. Hogan, R. L. Cerny, M. R. Boyd, D. L. Doubek, and J. M. Schmidt, *J. Nat. Prod.* in press; b) We are pleased to dedicate this contribution to Dr. Koji Nakanishi in commemoration of his 75th birthday; c) Midwest Center for Mass Spectrometry, University of Nebraska-Lincoln, Lincoln, Nebraska 68588-0362.
2. G. R. Pettit, J. K. Srirangam, J. Barkóczy, M. D. Williams, M. R. Boyd, E. Hamel, R. Bai, J.-C. Chapuis, and J. M. Schmidt, *Anti-Cancer Drug Design*, 1996, 10, 529.
3. G. R. Pettit, "The Dolastatins" in *Progress in the Chemistry of Organic Natural Products*, Vol. 70, Springer-Verlag, Wien-New York, 1997, pp 1-79.
4. J. E. Coleman, E. D. deSilva, F. Kong, R. J. Andersen, and T. M. Allen, *Tetrahedron*, 1995, 51, 10653.
5. M. Kobayashi, W. Wang, N. Ohyabu, M. Kurosu, and I Kitagawa, *Chem. Pharm. Bull.*, 1995, 43, 1598.
6. T. Ishida, Y. In, F. Shinozaki, M. Doi, D. Yamamoto, Y. Hamada, T. Shioiri, M. Kamigauchi, and M. Sugiura, *J. Org. Chem.*, 1995, 60, 3944.
7. G. R. Pettit, J. F. Day, J. L. Hartwell, and H. B. Wood, *Nature*, 1970, 227, 962.
8. G. Golakoti, J. Ogino, C. E. Heltzel, T. L. Husebo, C. M. Jensen, L. K. Larsen, G. M. L. Patterson, R. E. Moore, S. L. Mooberry, T. H. Corbett, and F. A. Valeriote, *J. Am. Chem. Soc.*, 1995, 117, 12030.
9. R. Fernández, J. Rodríguez, E. Quiñoá, R. Riguera, L. Muñoz, M. Fernández-Suárez, and C. Debitus, *J. Am. Chem. Soc.*, 1996, 118, 11635.
10. Conditions for the chiral HPLC analysis: column, CHIREX phase 3126 (4.6 x 50 mm; Phenomenex); solvents, 2 mM CuSO₄ aq. for α -amino acids and lactic acid, and 2 mM CuSO₄ aq/CH₃CN (9:1) for the 2-hydroxyisovaleric acid; detection at 230.4 and 550 nm. The retention times (min) of the authentic amino and hydroxy acids: L-MeVal (6.794), D-MeVal (10.910), L-Pro (8.612), D-Pro (18.800), L-Leu (39.420), D-Leu (69.891), S-Hiv (12.036) and R-Hiv (19.520).

11. G. R. Pettit, Z. Cichacz, J. Barkóczy, A.-C. Dorsaz, D. L. Herald, M. D. Williams, D. L. Doubek, J. M. Schmidt, L. P. Tackett, D. C. Brune, R. L. Cerny, J. N. A. Hooper, and G. J. Bakus, *J. Nat. Prod.*, 1993, 56, 260.
12. G. R. Pettit, J. K. Srirangam, D. L. Herald, J.-P. Xu, M. R. Boyd, Z. Cichacz, Y. Kamano, J. M. Schmidt, and K. L. Erickson, *J. Org. Chem.*, 1995, 60, 8257.

Received, 10th March, 1997